Literature DB >> 29424937

Pathogenesis of cranial neuropathies in Moebius syndrome: Electrodiagnostic orofacial studies.

Francis Renault1, Roberto Flores-Guevara2, Bernard Sergent3, Jean Jacques Baudon4, Jessie Aouizerate5, Marie-Paule Vazquez6, Cyril Gitiaux7.   

Abstract

INTRODUCTION: We designed a retrospective study of 59 patients with congenital sporadic nonprogressive bilateral facial and abducens palsies.
METHODS: Examinations included needle electromyography (EMG) of facial and oral muscles, facial nerve motor latency and conduction velocity (FNCV), and blink responses (BR).
RESULTS: Neurogenic EMG changes were found in 1 or more muscles in 55 of 59 patients, with no abnormal spontaneous activity. EMG changes were homogeneously neurogenic in 17 patients, homogeneously myopathic in 1 patient, and heterogeneous in 41 of 59 patients. Motor latency was increased according to recordings from 52 of 137 facial muscles. An increase of motor latency was not associated with neurogenic EMG (Fischer's test: right, P = 1; left, P = 0.76). FNCV was slowed in 19 of 36 patients. BR was absent bilaterally in 35 of 58 patients; when present, R1 and R2 latencies were normal. DISCUSSION: Our results support the hypothesis of an early developmental defect localized in motor cranial nerves with spared V-VII internuclear pathways. Muscle Nerve, 2018.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Moebius syndrome; brainstem; cranial nerves; electromyography; facial palsy

Year:  2018        PMID: 29424937     DOI: 10.1002/mus.26095

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  1 in total

1.  Differentiating Moebius syndrome and other congenital facial weakness disorders with electrodiagnostic studies.

Authors:  Tanya Lehky; Reversa Joseph; Camilo Toro; Tianxia Wu; Carol Van Ryzin; Andrea Gropman; Flavia M Facio; Bryn D Webb; Ethylin W Jabs; Brenda S Barry; Elizabeth C Engle; Francis S Collins; Irini Manoli
Journal:  Muscle Nerve       Date:  2021-01-19       Impact factor: 3.217

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.